Facebook
Twitter
LinkedIn

Media Center

CLSI and the Canadian Technology Accelerator Program Partner in Assisting Emerging Canadian Life Science Companies
Facebook
Twitter
LinkedIn

Iraina Miles from the Consulate General of Canada and Julie Harness of CLSI launch CTA In Market Program

The California Life Sciences Institute (CLSI) has partnered with the Canadian Technology Accelerator (CTA) San Francisco – Life Sciences to deliver a 16-week winter program that provides eight Canadian early-stage companies with customized mentorship and in-market programming to advance their commercialization strategies.  The San Francisco In Market Program kicked off on November 7-8 and will conclude with a Closing Program and Showcase in February 2019.

The Canadian Technology Accelerator-Life Sciences (CTA-LS) San Francisco is an intensive program run by the Consulate General of Canada in San Francisco, which offers high-potential Canadian companies – in biopharmaceuticals, digital health, medical devices, imaging, precision medicine/genetics, research tools, and diagnostics – strategic guidance and tailored resources to help expand their business in a global hub for the life sciences sector. CLSI was selected to help deliver the 2018-19 San Francisco CTA-LS program.

Alex Schuth, COO Denali, addresses the CTA cohort

The eight Canadian companies are Aifred Health, harnessing artificial intelligence to help physicians make better treatment decisions in mental healthcare; ExVivo Labs, developing skin patches and reader that can identify allergy sensitivities quickly, pain-free and without the need for a reaction on the patient’s skin; iBionics, developing the Diamond Eye implant, doing for blind people what the COCHLEAR® implant does for the deaf; Mediphage Bioceuticals, unlocking the potential of redosable genetic medicine with DNA ministrings, an elegant gene delivery vector platform; Nanostics, who have developed a novel liquid biopsy test for Prostate Cancer, which is twice as accurate and less invasive than existing tests; ProteinQure, designing new protein therapeutics through molecular dynamics simulations, quantum computing and machine learning; Serenity Bioworks, solving the redosing issue for gene therapies with a “reverse vaccine” approach; and Zilia, developing an innovative, non-invasive technological platform that uses imagery, spectrometry and artificial intelligence to measure in real-time oxygen saturation in the human eye – an important factor in diseases of the eye.

The Canadian partnership falls under CLSI’s FAST International program for non-US based life science clusters.  FAST International is intended to help foreign partners grow their regional economies by helping their life science startups gain commercial footholds in US markets, while enabling these startups to develop subsidiaries or commercial spin-offs in U.S. markets. For more information, contact skarp@califesciences.org.